Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Albumin-bound docetaxel versus Taxotere in previously treated advanced gastric or gastroesophageal junction adenocarcinoma
CTR20223068Phase 2Completed
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology
- Start
- Feb 2023
- Modality
- Small Molecules, Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
A Phase 2 trial of albumin-bound docetaxel in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, sponsored by CSPC ZhongQi Pharmaceutical Technology. Started Feb 2023; status: completed.
02
Drugs
albumin-bound docetaxel
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on CTR20223068.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20223068.